Rationale: Cardiomyocytes cultured in a mechanically active 3-dimensional configuration can be used for studies that correlate contractile performance to cellular physiology. Current engineered cardiac tissue (ECT) models use cells derived from either rat or chick hearts. Development of a murine ECT would provide access to many existing models of cardiac disease and open the possibility of performing targeted genetic manipulation with the ability to directly assess contractile and molecular variables.
O ver the last decade, techniques to culture neonatal rat and chick cardiac cells in 3-dimensional environments have been established and refined. [1] [2] [3] [4] [5] Three-dimensional engineered cardiac tissue (ECT) has several advantages over traditional monolayer (2-dimensional) culture methods in that cardiac cells within the ECT form well-aligned, mechanically and electrically integrated strips that more closely resemble functional myocardium. Thus, ECTs are well suited for a variety of applications, including disease modeling, drug discovery, and the study of basic myocardial physiology.
Recent research efforts have focused on optimizing ECT for applications in tissue-replacement therapy or as a platform for pharmacological screening. Techniques to do this have included the use of neonatal cardiac cells from different species, primarily rat and chick, as well as cardiomyocytes differentiated from mouse embryonic stem or induced pluripotent stem cells. [1] [2] [3] 6 Additionally, to promote cell survival and maintain differentiation, several different support matrices have been adopted, including solid scaffolds, [7] [8] [9] decellularized cardiac tissue scaffolds, 10 and stackable cardiomyocyte sheets, [11] [12] [13] which use a variety of combinations of different hydrogels, such as collagen I, fibrin, and fibrinogen. 1-5,14 -16 These modifications have given rise to ECTs in several different configurations, including rings, patches, cylinders, or even intact hearts, each optimized for its envisioned downstream application.
One of the earliest proposed applications of ECT was as a platform to study the physiological effect of gene ablation and genetic mutation on cardiac contractility. 2 Theoretically, using a knockout background, exogenous genes could be expressed in ECT through adenovirus-mediated gene transfer and the resulting impact on contractile function readily measured. 1, 2 However, although cardiac cells from rat myocardium are commonly used, to the best of our knowledge, ECT from neonatal mouse cardiac cells has not yet been established, and cardiac gene-manipulation studies continue to rely on whole-animal models and isolated 2-dimensional culture approaches. Clearly, establishing murine ECT would provide significant advantages by allowing study of the multiple existing genetic mouse models of cardiac disease. More importantly, murine ECT would permit the physiological characterization of mutations before the development of secondary changes (ie, hypertrophy, heart failure) that occur in older whole-animal and excised-tissue models.
One mouse model that has been studied extensively is that of cardiac myosin-binding protein C (cMyBP-C) ablation (cMyBP-C Ϫ/Ϫ ). cMyBP-C plays an important regulatory role in cardiac muscle contraction, and mutations in the cMyBP-C-encoding gene (MYBPC3) are prevalent causes of familial hypertrophic cardiomyopathy (HCM) in humans. [17] [18] [19] cMyBP-C Ϫ/Ϫ mice share several of the known phenotypes of the human disease, including pronounced left ventricular and septal hypertrophy, systolic and diastolic dysfunction, and accelerated contractile kinetics. 20 -26 Here, we present data showing successful generation of ECT from cardiac cells derived from wild-type (WT) and cMyBP-C Ϫ/Ϫ neonatal mouse hearts. We demonstrate that ECT derived from cMyBP-C Ϫ/Ϫ cardiac cells recapitulates several contractile abnormalities previously observed in both intact hearts and isolated cardiac tissue from cMyBP-C Ϫ/Ϫ mice. 20 -26 Importantly, these abnormalities occur in the absence of detectable hypertrophic remodeling. Additionally, we show that transduction of cMyBP-C Ϫ/Ϫ mouse ECT with an adenovirus that encodes WT human cMyBP-C completely mitigates the contractile abnormalities in these ECTs. Thus, we demonstrate a robust and reproducible mouse ECT model that provides a novel tool that bridges the gap between isolated cell culture and the intact heart. We further demonstrate the ability to apply this tool to the study of genetic mouse models of important human cardiac diseases.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Animals
Ventricular tissue was harvested from 1-day-old homozygous cMyBP-C Ϫ/Ϫ mouse pups that were previously generated on the E129X1/SvJ background 20 and from 1-day-old WT E129X1/SvJ mice (Taconic, Hudson, NY). Pups were anesthetized with inhaled isoflurane before ventricular tissue was harvested. This study was approved by the Animal Care and Use Committee of the School of Medicine and Public Health at the University of Wisconsin-Madison in accordance with the "Guide for the Care and Use of Laboratory Animals" (National Institutes of Health publication No. 85-23, revised 1985).
Isolation of Neonatal Mouse Ventricular Cardiac Cells
Ventricular cardiac cells were isolated by use of enzymatic dissociation based on methods used to isolate neonatal rat cardiomyocytes. 2, 3, 27, 28 Briefly, excised ventricular tissue was minced and suspended in 3 mg/mL collagenase type II (Gibco BRL, Invitrogen, Carlsbad, CA) in KG buffer (pH 7.4) and incubated at 37°C for 20 minutes with gentle agitation. KG buffer consisted of 127 mmol/L L-glutamic acid potassium salt monohydrate (Sigma, St Louis, MO), 0.1335% (wt/vol) NaHCO 3 (Gibco), 16.5 mmol/L D-glucose (Sigma), 0.42 mmol/L Na 2 HPO 4 (Sigma), and 25 mmol/L HEPES (Sigma). Ventricular tissue was subsequently resuspended and agitated in 0.1% trypsin (Gibco) in KG buffer for 10-minute intervals until dispersed. Cells were pelleted at 200g and resuspended in mouse culture media that consisted of 60.3% high-glucose DMEM (Gibco), 20% F12 nutrient mix (Gibco) supplemented with 1 mg/mL gentamicin (Sigma), 8.75% fetal bovine serum (HyClone; Thermo Fisher Scientific, Waltham, MA), 6.25% horse serum (HyClone), 1% HEPES (Sigma), 1ϫ nonessential amino acid cocktail (Gibco), 3 mmol/L sodium pyruvate (Gibco), 0.00384% (wt/vol) NaHCO 3 (Gibco), and 1 g/mL insulin (Sigma). Cell suspensions were preplated into P100 cell culture dishes and incubated at 37°C for 45 minutes to allow preferential attachment of nonmyocyte cell populations and enrichment of the cardiomyocyte population. Cardiac cells remaining in suspension were collected, checked for viability by dye exclusion, counted, and prepared for subsequent ECT construction.
Generation and Characterization of Human

MYBPC3-Expressing Adenovirus
An adenovirus encoding N-terminally Myc-tagged full-length human cMyBP-C (adWT) was generated with the ViraPower Adenoviral Expression System (Invitrogen) according to the manufacturer's protocol. The transduction efficiency of adWT was assessed in neonatal murine cardiac cells in 2-dimensional culture. Control viruses expressing the LacZ reporter gene (adLacZ) and lacking any significant reading frame (adC Ϫ ) were similarly prepared (see the Online Data Supplement for detailed methodology).
ECT Construction
WT and cMyBP-C Ϫ/Ϫ neonatal mouse ventricular cells suspended in mouse media were rotated at 50 rpm on a gyratory shaker (195 mm diameter) for 6 to 8 hours at 37°C and 5% CO 2 to allow aggregation of small, uniform clusters of viable cells. For production of cMyBP- 
Results
Structure of Murine ECT
Spontaneous contraction began in an uncoordinated manner on the second day after ECT construction, with gradual transition to coordinated rhythmic contraction by day 5. During the 7 days in culture, ECT diameter decreased from the mold width of 3 mm to approximately 1.1 mm as the construct formed and compacted ( Figures 1A and 1B ). Cells were distributed unevenly through the ECT, with elongated cardiomyocytes predominantly located near the surface, whereas noncardiomyocyte cell populations were distributed evenly throughout the ECT ( Figures 1C-F) . Cardiomyocytedense areas were often noted at the bottom of the ECT, presumably because of gravitational settling of the cardiomyocytes during matrix polymerization. 2, 29, 30 Cardiomyocytes in this region were particularly well defined, elongated, and rich in mitochondria, with the sarcomeres aligned to the long axis of the ECT (Figures 1 C-J) . Gap junctions were frequently noted between adjacent cardiomyocytes in these areas ( Figure 1J ). Additionally, isolated round cardiomyocytes with disorganized sarcomeric orientation were often observed closer to the center of the structure. There were no genotype-dependent differences in the final diameter (WT 
Physiological Response of WT Murine ECT
ECTs generated from rat and chick hearts recapitulate several aspects of the contractile phenotype of intact cardiac tissue. [1] [2] [3] 29, 31, 32 We therefore examined the contractile responses of murine ECT to standard physiological challenges. Maximal twitch force (F Max ) of mouse ECT increased in response to increasing stretch applied to ECT in accordance with the Frank-Starling law (Figures 2A and 2B ). Furthermore, ECT responded appropriately to an increase in perfusion temperature from 24°C to 37°C with a significant increase in F Max and the rate of contraction, assessed as the elapsed time between the electric pulse and peak developed twitch force (Ct 100 ). Increasing temperature similarly increased the rate of relaxation, assessed from elapsed time between peak developed twitch force and 50% twitch force decay (Rt 50 ; Figures 2C and 2D ). F Max decreased as stimulation frequency was increased from 4 to 8 Hz in mouse ECT incubated at 37°C. This negative force-frequency relationship was less pronounced at slower pacing frequencies (4 to 6 Hz; Figures 2E and 2F). The magnitude of twitch force generated by, and physiological responsiveness of, murine ECT was similar to that of similar ECT produced from rat cardiomyocytes. 33
Effect of cMyBP-C Ablation on Contractile Function
cMyBP-C ablation increases the rates of contraction and relaxation in both intact hearts and isolated papillary muscle, 20 -26 with an increase in power output noted in skinned cardiac fibers. 21 We therefore investigated the contractile properties of cMyBP-C Ϫ/Ϫ ECT. Contractile function was assessed in WT and cMyBP-C Ϫ/Ϫ ECTs that were electrically stimulated at murine physiological frequencies of 6, 7, and 8 Hz ( Figure 3 ). F Max was significantly greater in cMyBP-C Ϫ/Ϫ ECT than in WT ECT at all frequencies ( Figure 3B ; Online Table I ). Expression levels of several sarcomeric components were similar between WT and cMyBP-C Ϫ/Ϫ ECTs at both the transcript and protein levels (Figures 4 and 5; Online Figures VI, VII, and VIII), which indicates that increased force production by cMyBP-C Ϫ/Ϫ ECT is unlikely to be due to differences in cardiomyocyte number. Additionally, Ct 100 and Rt 50 were significantly shorter in cMyBP-C Ϫ/Ϫ than in WT ECT at all stimulation frequencies (Figures 3C and 3D ; Online Table I ), which indicates accelerated kinetics of contraction and relaxation in cMyBP-C Ϫ/Ϫ ECT.
cMyBP-C ؊/؊ ECT Represents "Prehypertrophic" HCM
Much of the contractile data characterizing the effects of genetic manipulation on heart function are necessarily derived from adult mice, which typically have already undergone notable hypertrophic remodeling. A potential advantage of ECT in studies of genetically manipulated cardiomyocytes is the relative immaturity of the cardiomyocytes at the time of isolation for ECT construction. To evaluate the status of our source cardiomyocytes, we first measured the heart-to-body weight ratio in newborn (postnatal day 1) and juvenile pups 
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Murine-Engineered cMyBP-C ؊/؊ Cardiac Tissuefrom WT and cMyBP-C Ϫ/Ϫ litters. Heart-to-body weight ratios were similar in neonatal WT and cMyBP-C Ϫ/Ϫ mouse pups (Online Figure IA) . By postnatal day 10, heart-to-body weight ratios were significantly higher in the cMyBP-C Ϫ/Ϫ pups and remained elevated at postnatal day 35 .
We used quantitative real-time polymerase chain reaction to examine expression of early (atrial natriuretic peptide [Nppa] and brain natriuretic peptide [Nppb] ) and long-term (␤-myosin heavy chain [Myh7] and ␣-myosin heavy chain [Myh6]) hypertrophic marker genes. In postnatal day 1 cMyBP-C Ϫ/Ϫ hearts, expression levels of Myh6 and Myh7 were not differentially regulated (Online Figures IB, C) , whereas expression of Nppa and Nppb was already significantly upregulated (Online Figures  ID, F) . This suggests activation of early hypertrophic pathways in the "prehypertrophic" myocardium. The expression profiles of hypertrophic marker genes confirmed the presence of overt cardiac hypertrophy in postnatal day 10 and day 35 cMyBP-C Ϫ/Ϫ mice (Online Figure I) . Because ECTs were isolated from postnatal day 1 pups, the initial expression levels of early-and late-hypertrophic genes would presumably be the same between the newly formed ECT and the postnatal day 1 hearts of the respective genotype; however, over the 10 days in vitro, ECT might progress along the same pathway as the intact hearts, which in the cMyBP-C Ϫ/Ϫ pups showed significant activation of hypertrophic signaling. We therefore examined WT and cMyBP-C Ϫ/Ϫ ECT for hypertrophic signals by quantitative real-time polymerase chain reaction. All marker genes (early and late) were expressed at similar levels in WT and cMyBP-C Ϫ/Ϫ ECT (Figure 4) , which indicates relative quiescence of hypertrophic signaling in cMyBP-C Ϫ/Ϫ ECT.
Adenovirus-Mediated Expression of Human cMyBP-C Restores Contractile Function in cMyBP-C ؊/؊ ECT
Two-dimensional cultures of WT ventricular myocytes were transduced with an adenovirus that expressed Myc-tagged WT human cMyBP-C (adWT). Quantitative real-time polymerase chain reaction was used to determine the expression of endogenous (murine) and exogenous (human) cMyBP-C over a range of MOIs. Expression of human and murine cMyBP-C was similar at an MOI of 5, whether using a standard curve method ( Figure 5A ) or expressed as a fraction of ␤-actin expression levels with the ⌬-⌬Ct method (data not shown). Furthermore, expression of the human MYBPC3 transgene did not have a significant effect on endogenous mouse Mybpc3 mRNA levels, irrespective of MOI ( Figure  5A ). Expression of human MYBPC3 was, however, significantly higher than that of endogenous mouse Mybpc3 at Ͼ5 MOI ( Figure 5A ). We then examined protein expression by Western blot analysis using an anti-cMyBP-C antibody. Total cMyBP-C and myosin heavy chain protein levels were assessed in untransduced WT cardiac cells and cMyBP-C Ϫ/Ϫ cardiac cells transduced at MOIs of 0, 5, 10, 20, 50, and 100 in 2-dimensional culture. Human cMyBP-C protein levels were expressed as a fraction of myosin heavy chain protein level and compared with endogenous mouse cMyBP-C levels in untransduced WT cardiac cells. cMyBP-C levels in transduced cMyBP-C Ϫ/Ϫ cells at MOIs of 5, 10, or 20 did not significantly differ from cMyBP-C levels in untransduced WT cells. Transduction at higher MOIs resulted in significantly higher cMyBP-C levels ( Figure 5B ). Transduction of cardiac cells with adWT adenovirus did not significantly affect cell survival, as assessed by reduction of 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT assay), at any MOI used (Online Figure IIIB) . Additionally, LacZ reporter-gene expression in mouse neonatal cardiac cells transduced with the adLacZ control virus was assessed by ␤-galactosidase assay 48 hours after transduction. Transduction efficiency approached 100% at an MOI of 5, whereas transduction at higher MOIs resulted in more intense staining, likely due to ␤-galactosidase buildup in the cytoplasm (Online Figure II) . Transduction with adLacZ had a modestly adverse effect on cell survival, as assessed by an MTT assay, that was statistically different from untransduced cells at MOIs of 10 and 100 (Online Figure IIIA) .
We chose to use an MOI of 20 for subsequent generation of ECT because even marginally lower cMyBP-C protein levels have been shown to cause HCM in humans. 17 Transduction was performed during the 8-hour rotational culture. Quantitative Western blots confirmed the presence of equivalent cMyBP-C levels in untransduced WT ECT and cMyBP-C Ϫ/Ϫ adWT ECT, whereas signal was absent from untransduced cMyBP-C Ϫ/Ϫ ECT ( Figure 5C ). To confirm that exogenous human cMyBP-C normally inserted into the sarcomere, we used immunofluorescence microscopy to detect endogenous and human cMyBP-C. WT 
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ECT showed a double cross-striated pattern, characteristic of C-zone-specific incorporation of cMyBP-C into the sarcomere ( Figures 6B and 6C ). The double cross-striated cMyBP-C staining pattern was restored after adWT transduction in cMyBP-C Ϫ/Ϫ ECT ( Figures 6H and 6I ). This labeling pattern was absent in untransduced cMyBP-C Ϫ/Ϫ ECT constructs incubated with the same anti-cMyBP-C antibody ( Figures 6E and 6F ). These data indicate that exogenous human cMyBP-C is appropriately incorporated into the mouse sarcomere in ECT constructs.
One of the major difficulties with genetically engineered mice is determining whether the phenotype is entirely due to deficiency of the specific gene or to secondary remodeling events. We therefore sought to determine whether adenovirus-mediated transduction of human cMyBP-C could rescue the physiological deficits identified in the cMyBP-C Ϫ/Ϫ ECT. F Max in cMyBP-C Ϫ/Ϫ adWT ECT was restored to levels similar to that of WT ECT at all stimulation frequencies and was significantly lower than that of cMyBP-C Ϫ/Ϫ ECT ( Figure 7B ; Online Table I) . Furthermore, Ct 100 and Rt 50 in cMyBP-C Ϫ/Ϫ adWT ECT were similar to those of WT ECT and significantly longer than those of cMyBP-C Ϫ/Ϫ ECT at all 3 pacing frequencies (Figures 7C and 7D ; Online Table I ), whereas transduction of cMyBP-C ECT with the adC Ϫ control virus failed to alter these parameters (Online Figure IV) . We found no genotype-dependent differences in total protein or RNA yields (Online Figure VI, A and B) , whereas expression levels of total myosin heavy chain protein and Myh6 transcript levels were not influenced by ECT genotype (Online Figure VI, C and D) , which indicates that functional differences are unlikely to be due to total cell or cardiomyocyte number. Additionally, expression levels of several genes that encode sarcomeric proteins or proteins involved in excitation-contraction coupling were similar in WT, cMyBP-C Ϫ/Ϫ , and cMyBP-C Ϫ/Ϫ adWT ECT (Online Figure VIII) . These findings confirm that exogenous human cMyBP-C can incorporate into the mouse sarcomere and restore normal physiological function. Furthermore, these data reinforce the idea that the physiological abnormalities identified in the cMyBP-C Ϫ/Ϫ ECT are specifically due to the deficiency of cMyBP-C and not to compensatory mechanisms.
Discussion
The data presented herein demonstrate the feasibility of applying 3-dimensional culture methods in the study of both murine and human cardiac physiology and of validating a novel method to obtain fundamental contractile data from "unremodeled" cardiomyocytes that carry mutations that lead to HCM. Furthermore, we have demonstrated the feasibility of introducing sarcomeric proteins into a multicellular cardiac muscle preparation with the potential to develop a robust screening system for genetic cardiac disease.
Generation of Murine ECT
To the best of our knowledge, this is the first report describing ECT generated from neonatal mouse cardiac cells. As described here, the murine ECT provides a powerful, high-throughput tool to test how specific alterations in cardiac genes contribute to abnormal cardiac physiology and produce disorders such as HCM and dilated cardiomyopathies. Although our approach was similar to those used previously for the generation of rat ECT, 2,4 we found several adaptations that were essential for the generation of wellorganized, functioning mouse ECT. First, viability and quality of the resulting ECT were improved when cells were harvested from mouse pups less than 24 hours old. In agreement with previous studies, 3, 4 we also observed that incubation of mouse cardiac cells with gentle gyration (rotational culture) to allow aggregation of the isolated cells was beneficial to establishing mechanically active ECT. However, whereas previous studies maintained cells in rotational culture for more than 12 hours, 3, 4 we found that a culture period of 6 to 8 hours yielded more uniform small clusters of cells and reduced excessive cell death. Third, seeding neonatal mouse cardiomyocytes at a density of 8ϫ10 5 per ECT with a concentration of 4ϫ10 6 cells/mL was necessary to establish robust muscle strips that extended the length of the construct. This optimal seeding density was similar to that used to produce fibrin-based rat ECT (4.1ϫ10 6 cells/mL) 5 but higher than previously used for the generation of chick (1.3ϫ10 6 cells/mL) 1 and rat (3.2ϫ10 6 cells/mL) 2 ECT in collagen matrices. Generally, cardiac cells from 4 to 5 neonatal hearts were required for each ECT generated. Finally, we found that addition of F12 nutrient supplement mixture to the culture media during the extended 7-to 10-day culture period was essential for optimal cell viability.
Mouse ECT produced measurable force, accepted electric pacing, and responded appropriately to physiological stimuli, including increases in passive tension and temperature. This is not surprising given that cardiomyocytes in mouse ECT align with the long axis of the construct and form myofibrils that span the length of the ECT, with preserved sarcomeres, abundant mitochondria, and numerous gap and tight junctions. This level of organization observed in mouse ECT is distinctly absent from the stellate cardiomyocytes commonly observed in monolayer cultures. As in other species, [1] [2] [3] 29, 31, 32 mouse cardiomyocytes in the ECT responded appropriately to increasing stretch in accordance with the Frank-Starling law. Similar to observations in intact myocardial tissue, 34 -36 increasing the perfusion temperature to 37°C significantly accelerated the rates of contraction and relaxation in mouse ECT. The ability to acquire measurements under physiological conditions is crucial to drawing physiologically relevant conclusions about contractile kinetics. ; A, D, G) . cMyBP-C was detected by rabbit anti-cMyBP-C primary antibody and AlexaFluor 488 goat anti-rabbit secondary antibody (green fluorescence; B, E, H). Panels C, F, and I represent desmin and cMyBP-C immunofluorescence overlay. DAPI was used as a nuclear counterstain in all panels (blue fluorescence). Scale bars, 10 m.
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Unlike intact neonatal and adult mouse cardiac tissue, mouse ECT did not display a positive force-frequency response. 6, [37] [38] [39] [40] Indeed, the force frequency tended to be negative in mouse ECT, a phenomenon that was more striking at higher pacing frequencies. Similar negative force-frequency relationships were noted previously in rat ECT. 2, 6, 32 This negative force-frequency relationship may be a result of the dimensions of ECT constructs. Previously, Janssen et al 36 showed a positive force-frequency response in ultrathin rat trabeculae but a flat or negative relationship in trabeculae with a diameter of Ͼ100 m, specifically at higher pacing frequencies. They speculated that diffusion of oxygen and nutrients, as well as removal of toxic metabolites, may become limiting at higher pacing frequencies when diffusion distances exceed Ϸ50 to 75 m, resulting in a negative force-frequency relationship. 36 Because mouse ECT are generally approximately 1 mm in diameter, and well-organized cardiomyocyte-rich cell layers often exceed 100 m, diffusion distance may account for the negative force-frequency response in ECT derived from mice and from other species.
Further refinement of the mouse ECT model is desirable to achieve a more defined growth environment. Current methods of culturing rat ECT have successfully reduced or eliminated serum from the growth media by substituting a complex cocktail of supplements. 14 Attempts to replace serum in the mouse cultures have not been successful thus far. Additionally, alternatives to the collagen matrix and Matrigel have been explored in rat ECT. 5,14 -16 Most promising is the use of fibrin, which supports better cell survival and more uniform final tissue configuration. Fibrin also appears to undergo more extensive remodeling by the cardiomyocytes and nonmyocytes within the ECT, which likely results in a more physiological extracellular matrix than achieved with collagen. 5, 15 The distribution of cardiomyocytes around the outer margin of the ECT is commonly observed in collagenbased ECT. 2, 29 This likely reflects both the gradient of nutrients and oxygen, which diminish 50 to 100 m from the outer surface of the construct, 36, 41 as well as a settling of cells as the collagen matrix slowly polymerizes. 29 Development of a fibrin-based matrix might reduce this phenomenon, because the fibrin polymerizes more quickly, maintaining a better distribution of cardiomyocytes throughout the full cross section of the ECT. 5 Finally, the murine ECTs are typically 
Specific Physiological Functions of cMyBP-C
Mutations in MYBPC3 are a common cause of human familial HCM, with more than 150 distinct mutations implicated thus far. [17] [18] [19] The impact of most of these mutations on cardiac function remains unknown, mainly because of the prohibitive cost and time required to generate mouse models that express specific gene mutations. The murine ECT cMyBP-C Ϫ/Ϫ model, in which human mutations can be introduced and characterized, therefore provides a readily accessible tool to screen disease-causing mutations. The cost is comparatively low, and the time from design to physiological testing is approximately 3 months.
Our initial application of the murine ECT to study human disease has focused on the cMyBP-C Ϫ/Ϫ mouse precisely because it is a well-characterized mouse model of cardiomyopathy. Overall, cMyBP-C ablation does not affect birth frequency or long-term survival of cMyBP-C Ϫ/Ϫ mice. 20 However, at the whole-organ level, cMyBP-C ablation causes significant cardiac hypertrophy, myocytic disarray, fibrosis, and impaired left ventricular fractional shortening and ejection fractions. 20, 26, 45 The accelerated rates of contraction and relaxation we have identified in cMyBP-C Ϫ/Ϫ ECT are similar to contraction kinetics observed in isolated skinned myocardium from cMyBP-C Ϫ/Ϫ hearts. 20 -26 The increased F Max in cMyBP-C Ϫ/Ϫ ECT contrasts with the impaired left ventricular fractional shortening and ejection fractions in the intact cMyBP-C Ϫ/Ϫ heart and the F Max observed in isolated skinned fibers, which was similar between the WT and MyBP-C Ϫ/Ϫ preparations 20, 22, 26, 45 ; however, in those studies, functional measurements were generally performed in tissue derived from older hearts that had already undergone hypertrophic remodeling, fibrosis, and changes in extracellular matrix elasticity. The present data are, however, consistent with findings by Korte et al, 21 who showed an increase in power output in skinned cMyBP-C Ϫ/Ϫ fibers. This is compatible with a model in which cMyBP-C ablation increases the probability of cross-bridge formation, as was previously proposed, 24 -26 and supports the assertion that ECT may accurately reflect the inherent contractile properties of cardiomyocytes before remodeling and not the consequences of remodeling and other secondary events. Our findings also suggest that the ECT model may be well suited to examining the chain of events that lead from the initial genetic mutation and contractile phenotype to the manifestation of hypertrophy and heart failure. Future experiments will focus on further evaluation of this model of early MYBP-C deficiency, with careful assessment of other factors that may contribute to contractile performance, such as the phosphorylation status of sarcomeric proteins. Although we would not expect there to be differences between overall cMyBP-C Ϫ/Ϫ and WT ECT protein phosphorylation, this remains to be fully explored, because potential differences could have important effects on both F Max and contractile kinetics. Rescue of normal physiology by adenovirus-mediated expression of WT human protein confirms that our findings are due specifically to absence of cMyBP-C. Importantly, virally expressed protein incorporated normally into the sarcomere. By transducing cells during the rotational cultures, we ensured that exogenous human cMyBP-C in cMyBP-C Ϫ/Ϫ adWT ECT was expressed at levels that were nearly identical to those of the endogenous protein in WT ECT without causing a significant reduction in cell survival. Immunohistochemical analysis of cMyBP-C Ϫ/Ϫ adWT ECT showed a uniform transduction efficiency of most of the cells throughout the construct, with exogenous human cMyBP-C appropriately incorporated into the sarcomeric C-zones. A similar approach will be used in future studies to assess the contractile effects of expressing human HCM mutant cMyBP-C on the cMyBP-C Ϫ/Ϫ background. On the basis of these data, we suggest that other sarcomeric proteins causative of human HCM can be similarly expressed and appropriately incorporated into murine ECT models derived from corresponding knockout animals.
In conclusion, we have developed a mouse ECT model for investigations of cardiomyocyte physiology and pathophysiology. We have shown that cMyBPC Ϫ/Ϫ ECTs recapitulate the accelerated contractile kinetics observed in isolated muscle from cMyBPC Ϫ/Ϫ mice in the absence of hypertrophic remodeling, thus confirming the fundamental contractile phenotype of cMyBP-C ablation. Furthermore, we have demonstrated the ability to introduce human sarcomeric proteins onto a knockout murine background. Murine ECT represents a new tool that bridges the gap between traditional isolated 2-dimensional cardiomyocyte cell culture and intact animal models. This technique will allow generation and characterization of novel genetic models more efficiently and at significantly less cost than with traditional animal models. This model could also provide an opportunity to study mutations that result in embryonic lethality in traditional animal models. More importantly, this model permits determination of the basic contractile phenotype in the absence of significant remodeling. Collectively, the strengths of this technique have the potential to increase our understanding of integrated cardiac physiology in health and disease.
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